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Summary Twelve of 648 patients in the Medical Research Council's first two trials in myelomatosis have
developed myelodysplasia or acute leukaemia. This corresponds to a 5-year actuarial prevalence of 3% and
an 8-year prevalence of 10%. Patients were randomised to treatment with either melphalan or
cyclophosphamide and the relative capabilities of these two drugs to cause these conditions were examined as
a function of duration of treatment. A significant relationship with length of melphalan treatment was found
but no relationship was observed for cyclophosphamide treatment. The amount of melphalan treatment given
in various intervals before diagnosis of myelodysplasia or leukaemia was studied and it was found that the
amount of treatment in the most recent 3-year period was the most important determinant of risk
(P=0.0001). It is estimated that the risk of haemopoietic neoplasia after 10 years of follow-up is about 3%
for each year of melphalan treatment and that much of this risk will occur within three years of the last
treatment.
The fact that treatment with cytotoxic agents can induce
myelodysplasia (MDS) and acute myeloid leukaemia (AML)
in patients suffering from cancer and from other diseases has
now been thoroughly documented (Kyle et al., 1970; Reimer
et al., 1977; Casciato & Scott, 1979; Berk et al., 1981;
Coltman, 1982; Green et al., 1982; Pedersen-Bjergaard &
Larsen, 1982; Boice et al., 1983; Boivin & Hutchinson, 1984;
Lakhani, 1984). However, quantitative relationships with the
dose and duration of treatment for different agents, and the
relative oncogenic potential of different drugs have yet to be
clearly elucidated. It is also not known whether susceptibility
to this outcome is influenced by the condition being treated.
As a class, the alkylating agents have been shown to be
particularly capable of inducing MDS and AML, and there
are many reports of both cyclophosphamide and melphalan
inducing MDS and AML in patients with mylelomatosis and
other neoplasms (Kyle et al., 1970; Gonzalez et al., 1977;
Bergsagel et al., 1979; Casciato & Scott, 1979; Buckman et
al., 1982; Coltman, 1982). A quantitative comparison of the
relative potency in doing so of these two drugs is more
difficult to obtain. In the first two trials in myelomatosis of
the Medical Research Council's Working Party on
Leukaemia in Adults patients were allocated at random to
be treated by either cyclophosphamide or melphalan, and the
long-term follow-up of these patients offers a rare
opportunity to assess the relative oncogenic potential of
these two drugs.
Patients and methods
The population at risk comprised all patients randomised in
the first two Medical Research Council trials (MRC, 1973;
MRC, 1980a).
Entry to the first trial began in October 1964 and closed in
August 1968 after 276 patients had been randomised. The
second trial entered 372 patients between September 1968
and May 1975. A total of 648 patients were entered into
these two trials. Patients in the first trial were randomised
between melphalan 4mg/day oral or cyclophosphamide
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150mg/day oral. In the second trial a 3-way randomisation
was employed: cyclophosphamide as above vs. melphalan
10mg/day oral for 7 days repeated every 4-6 weeks vs. the
same schedule of melphalan plus prednisone 40mg/day, oral
for 7 days repeated every 4-6 weeks. Patients who failed to
respond or who relapsed were treated at the physician's
discretion, so that allocated treatment is not a reliable guide
to total therapy, especially in long term survivors.
Evidence of MDS or AML was sought from routine
follow-up reports to the trial headquarters. In addition the
clinical notes of all five-year survivors and all patients
developing MDS or AML were used to abstract details of all
chemotherapy, including specific drugs and combinations
and the exact sequences of times on and off therapy. The
diagnosis of MDS or AML was reviewed by one of us
(D.A.G.G.) and confirmed where possible by review of
blood films and bone marrow aspirates. Bone marrow
investigations were performed only on patients who
developed unexplained cytopaenia.
In examining the blood and bone-marrow films, the
diagnosis of MDS or AML was made according to the
proposals of the French-American-British (FAB) cooperative
group (Bennett et al., 1982). In brief, the diagnosis of
leukaemia was made only when blast cells accounted for
>30% of the nucleated cells in the bone marrow; when the
blast-cell count was 5-20% the condition was diagnosed as
refractory anaemia with excess of blasts (RAEB) and when it
was .20% but <30% as RAEB in transformation (RAEB-
t). Myeloma cells were omitted in performing the differential
counts. The slides from one patient from the first MRC trial
had been examined for our first follow-up study (Buckman
et al., 1982) and the diagnosis was of MDS and AML, but
the slides were not available for review on this occasion.
Slides were available for review for 3 of the remaining five
patients from the first trial and this led to revision of the
diagnosis from MDS and AML to MDS alone in all three.
The slides from all patients in the second trial were reviewed.
Statistical methods
The main method of analysis was the proportional hazards
model with time-varying covariates (Cox, 1972). This, in
effect, compares the total amount of different drugs received
by a patients at the time of diagnosis of MDS or AML with
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that of all other patients who has survived for at least as
long. Note that the drug histories for these other patients are
truncated at a follow-up time equal to the diagnosis time for
the case. Thus they will vary from case to case. Also note
that a patient destined to become a case in the future is still
included in the control sets for previous cases. The model
produces a regression equation giving the increased hazard
(risk) of MDS or AML as a function of the duration of
treatment with each drug.
The usual relative risk function is not appropriate for this
problem because it assumes an exponential dose-response
curve which would imply that risk increases exponentially
with duration of treatment. A linear relationship is more
appropriate and leads us to consider a model of the form
A(t,zt) =AJO( ( +flzt) (A.1)
where zt denotes the exposure variable value at time t and
A0(t) is the background rate. Because the treatment related
effects were so large as to overwhelm the spontaneous
background rate this model was numerically unstable and a
simpler model assuming a zero background rate was used,
viz.
)(t,zt) = .o(t)Z. (A.2)
In this model the regression parameter # cannot be estimated
because it is confounded with the baseline hazard )4(t), but
predicted incidence curves can still be created and the
significance of the treatment variable zt can be assessed by
means of the likelihood ratio test comparing (A.2) with the
model (A.1) with P/=0.
This gave a better fit than using the standard exponential
relative risk model and linearity was checked by fitting the
model
A(t, Zt) =Ao(t)(Zt)1- (A.3)
The risk associated with cyclophosphamide was examined by
looking at the model
)(t,;,yt) = 0 (t)(zt+byt) (A.4)
where Yt measured cumulative duration of treatment with
cyclophosphamide. The estimated value for 6 was negative,
although non-significantly so, implying the cyclophos-
phamide treatment was not predictive of the risk of MDS or
AML in these data.
These models can also be used to predict the prevalence of
MDS or AML at given follow-up times. Prediction based on
relative risk models will consist of jumps at the observed
event times, and in order to get a smoother prediction curve,
an absolute risk model was also used. In effect this assumes
the baseline hazard rate to be constant and allows one to
compute an absolute risk for a given duration of treatment.
The model takes the specific form
A(t,z,) =az,. (A.5)
The maximum likelihood estimate of a is given by
&=N{ZJz(s)ds}
where N is the number of cases of MDS or AML, ti is the
follow-up time (to MDS, death, or censoring) of every
individual in the cohort and the sum is over all individuals
in the cohort. This model requires knowledge of the
treatment variable at all follow-up times. At early follow-up
times this was available only for a sample of the risk set and
we have made a correction assuming that the sample values
are representative of the entire risk set. This assumes that the
early treatment of long term survivors is representative of
the entire risk set.
The Wilcoxon rank-sum test is also used (Armitage, 1971)
and a generalization of it to treat multiple strata was used to
give a nonparametric ranking test for association between
MDS or AML and length of time on chemotherapy (Cuzick,
1985). All significant levels are based on 2-sided tests.
Results
Twelve patients were found to have developed MDS (9
cases) or MDS and AML (3 cases). Of the nine MDS cases,
six were instances of RAEB and three of RAEB-t. There
were no cases of refractory anaemia with or without ring
sideroblasts or chronic myelomonocytic leukaemia. In this
report all twelve patients who developed MDS or AML
(who will be referred to as 'cases' below) are considered as
a single group. Details are shown in Table I. The first case
occurred 36 months after entry into the trial and eight of the
cases occurred after five years or more of follow-up. The
clinical notes of all five-year survivors were sought and
details of chemotherapy were abstracted. A total of 103 out
of 648 patients in the first two trials survived at least five
years. The average follow-up time of the five-year survivors
was 97 months and ten patients were still alive on 1st
January 1985, at which time follow-up was censored. Of the
103 five-year survivors, full chemotherapy data were avail-
able on 97 (94%) and 89 of these patients showed no
evidence of MDS or AML. This last group of patients will
be referred to as controls. An additional 106 patients sur-
vived three but not five years without evidence of MDS or
AML. Strictly speaking they comprise part of the control
group (risk set) for the patients who develop MDS or AML
in the third and fourth year of follow-up. Their records were
not abstracted for logistic reasons, and a re-analysis of the
data omitting patients developing MDS or AML between
the third and fifth year did not appreciably change the
results. Thus we feel very little bias was introduced by this
omission.
In Figure 1 the crude (unadjusted for covariates) actuarial
cumulative incidence of MDS or AML is plotted. The
incidence is 3% after five years of follow-up, 10% after eight
years, and 20% after ten years although this last figure has a
large standard error (±6%). There figures are less than
those reported by Bergsagel et al., 1979.
None of the presentation features of the patients who
developed MDS or AML differed significantly from those of
the other three-year survivors. In the first three years of
follow-up cases received cytotoxic treatment for an average
of 34.0 months which did not differ significantly from the
31.6 months on treatment for controls (see Table II).
3 4 5 6 7 8 9 10
Time from diagnosis (years)
Figure 1 Actuarial prevalence of MDS or AML in all patients
in the first two medical Research Council's trials in
myelomatosis. Bars at each event denote standard errors of the
estimates.ACUTE LEUKAEMIA IN MYELOMATOSIS 525
Table I Clinical details of the twelve patients developing myelodysplasia or acute leukaemia
Age at intervalfrom Paraprotein
diagnosis diagnosis to level at Blood
ofmyeloma Paraprotein MDS or AML diagnosis urea Haemoglobin
Sex (years) Diagnosis type (months) (gl -1) mmoll-1 gl- Cytotoxic treatment
First trial
1 M 59 RAEB AK 122 9 2.7 146 Daily CYCLO 28mths from 3.65
Daily MEL 2mths from 10.67
Daily MEL 6mths from 3.69
Daily CYCLO 32mths from 8.70
Daily MEL 17mths from 8.73
2 M 61 RAEB-t GK 93 11 5.7 140 Inter. MEL 85mths from 7.68
3 F 67 RAEB-t AK 71 43 5.8 92 Daily MEL 72mths from 6.65
4 M 54 MDS/AML GA 57 54 4.1 117 Daily MEL 54mths from 3.67
5 F 65 MDS/AML GK 51 37 8.3 99 Daily CYCLO 1 mth from 7.67
Daily MEL 30mths from 4.68
6 M 64 MDS GA 51 13 5.5 135 Daily MEL 35mths from 4.68
and AML Daily CYCLO 1 mth from 3.71
ACTIN-D, CCNU 3mths from
3.72
Second trial
7 M 64 RAEB GA 36 55 5.0 105 Inter. MEL 31 mths from 6.72
DVB 17mths from 2.75
8 M 67 RAEB GK 78 19 5.3 142 Inter. MEL 75mths from 3.69
9 F 78 RAEB AK 95 25 6.6 122 Inter. MEL 93mths from 6.72
10 M 62 RAEB GA 106 62 6.1 123 Daily CYCLO 45mths from 10.70
Inter. MEL 5days from 7.74
Inter. MEL 55mths from 12.74
11 M 62 RAEB-t AK 109 30 6.0 125 Inter. MEL 103mths from 6.73
12 M 57 RAEB GA 118 31 5.0 124 Daily CYCLO 26mths from 11.72
Inter. MEL+VIN 9mths from
9.81
ARA -C =Cytosine arabinoside
THIO =6-Thioguanine
ACTIN-D=Actinomycin D
VIN =Vincristine
DVB =Doxorubicin, Vincristine, Bleomycin
MDS =myelodysplastic syndrome
RAEB =refactory anaemia with excess of blasts
RAEB-t =RAEB in transformation
AML =acute myeloid leukaemia
CYCLO=cyclophosphamide
MEL=melphalan
CCNU=lomustine
Table II Average number of months on cytotoxic therapy, melphalan treatment, and cyclophos-
phamide treatment, with standard errors, for the first 3 years of follow-up, and for all follow-up times
according to whether or not MDS or AML subsequently developed
All cytotoxic All Intermittent Daily
Group therapy melphalan melphalan melphalan Cyclophosphamide
First 3 years
All
patients 31.9 19.3 12.8 6.5 12.5
(se) (0.8) (1.6) (1.6) (1.3) (1.5)
Cases (n= 12) 34.0 25.9 17.6 8.3 7.7
(se) (1.1) (4.5) (5.3) (4.3) (3.9)
Controls (n=89) 31.6 18.4 12.2 6.2 13.2
(se) (0.9) (1.8) (1.7) (1.4) (1.7)
Allfollou-up
All
patients 64.6 40.6 27.7 12.9 23.2
(se) (2.9) (3.5) (3.3) (2.8) (2.8)
Cases (n=12) 70.2 57.2 45.2 12.0 11.2
(se) (8.3) (8.8) (12.1) (5.5) (6.0)
Controls (n=89) 63.8 38.4 25.3 13.1 24.8
(se) (3.1) (3.8) (3.4) (3.1) (3.1)
However, cases received melphalan for an average of 25.9
months which was significantly longer than for controls who
received the drug for an average of 18.4 months (2P=0.05,
Wilcoxon rank-sum test). The difference was mostly made
up from the greater time on cyclophosphamide in controls
(13.2 vs. 7.7 months). Similar differences were seen when the
total number of months of therapy were compared between
the groups, although the interpretation of these data is
complicated by the different survival times of the two
groups. More complete details are given in Table II.
Duration of melphalan treatment for each case and
corresponding values for controls at risk at that time are
shown in Figure 2.
A number of regression models for assessing length of526 J. CUZICK et al.
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Figure 2 Months of treatment with melphalan in cases and controls. Values for each case are given 0 and are compared to
values for all controls at the same follow-up time. Only individuals 'at risk' at follow-up time for each case are included.
treatment were studied. The details are elaborated in the
Statistical methods section. A proportional hazards model
assuming a linear increase in risk with duration of treatment
was used (eqn. A.2) and this was compared to a model
assuming risk was unrelated to dose by the likelihood ratio
test. When this was done using cumulative months of
melphalan treatment as the exposure variable, the likelihood
ratio chi-square was 5.81. This corresponds to an
approximate significance level of 0.02.
Linearity of risk with dose was checked by fitting the
model (A.3). A value of y= 1 corresponds to linearity and
the estimated value was y=0.42. This was not significantly
different from y=1, but suggestive that risk did not grow
linearly with total duration of treatment.
The risk associated with cyclophosphamide treated was
examined by looking at the model (A.4). No risk could be
associated with treatment using this drug. In a similar way
melphalan treatment was broken down into two variables -
months of daily treatment and months of intermittent
treatment. Both items had very similar coefficients (that for
daily treatment being 90% of the value for intermittent
administration). We concluded that these two modes of
administration were similar in their ability to induce MDS or
AML, and that they could be combined when assessing
duration of treatment.
We have pursued the question of duration of exposure
further by examining the predictive value of the amount of
treatment given in the period 3 or 5 years before the
development of MDS or AML (and a similar interval in
controls). These results are summarised in Table III and are
plotted for the 3-year period in Figure 3. In general the
relationship to melphalan was strengthened in each case. The
strongest relationship was found by looking at the amount
of melphalan in the three years before developing MDS or
AML (LRX2=16.72, 2P=0.0001) although the results were
almost as strong when a 5-year window was used
(LRX2 = 12.97, 2P=0.0003). When assessed by the nonpara-
metric ranking technique (Cuzick, 1985) the duration of
melphalan treatment in the past three years was also highly
significant (2P=0.005). After allowing for the duration of
melphalan treatment in the past three years, no predictive
value could be found for previous treatment with any
cytotoxic agent or previous melphalan treatment either
considered alone or as an interaction with melphalan
Table III Summary for a model of the form 2(t,z)= 2O(t)zy where z denotes months of
therapy in the specified treatment window. The first three columns consider the linear model
obtained by setting y=1 and compare the model to one assuming no effect of treatment, i.e.
A(t,z) =A,(t). The last three columns consider the model in which y is estimated from the
data. All P values are 2-sided. Non-parametric P values are computed according to Cuzick
(1985).
Approx.
LR Non- P value
chi-square Approx parametric LR for y I1
Model (y= 1) P value P value y X Vs y=
Cumulative melphalan 16.72 0.0001 0.005 0.80 16.86 >0.5
in last 3 years
Cumulative melphalan 12.97 0.0003 0.01 0.83 13.09 >0.5
in last 5 years
Cumulative melphalan
since diagnosis 5.81 0.02 0.08 0.42 7.34 0.21
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Figure 3 Months of treatment with melphalan in previous 3-year period for cases and controls. Values for each case are given ()
and are compared to values for all controls at the same follow-up time. Only individuals at risk at follow-up time for each case are
included.
treatment in the most recent three years (Data not shown).
Also there was still no relationship with duration of cyclo-
phosphamide treatment when therapy in the previous 3- or
5-year interval was analyzed.
An attempt has been made to predict the incidence of
MDS or AML as a function of the duration of melphalan
treatment. With so few data as these, the predictions must be
taken more as working approximations rather than absolute
estimates. The models used are simplified idealizations. For
example, the observation that duration of melphalan
treatment in the last three years gave a more significant
effect than total duration of treatment, should not be taken
to imply that the risk of MDS or AML is zero after three
years off treatment, but only that it is much reduced.
While not being quite as significant, the amount of
treatment in the past 5 years is likely to be a better model
for prediction. Accordingly, we have used the absolute risk
model with a 5-year treatment window for the predictions in
Figure 4. The predicted prevalence of MDS or AML in the
absence of other causes of death are plotted as a function of
follow-up time for the following model treatment schedules:
1, 2, 3, or 5 years of treatment and then stopping, indefinite
treatment, and treatment in alternate years (i.e. 1, 3, 5, etc).
At five years follow-up the predicted prevalence of MDS or
AML was 2.7%, 4.8%, 6.2% and 7.4% for patients treated
for 1, 2, 3, and 5 years respectively. At 10 years the estimates
were 3.0%, 6.0%, 8.8%, 14.2% respectively and patients
treated continuously for ten years had a 20.6% prevalence.
The prevalence on the alternating schedule was 4.5% at 5
years and 11.6% at 10 years. Comparable results were
obtained with the discrete proportional hazards model (eqn.
A.2), but the curves are less easily interpreted step functions.
As a rough guide, it would appear that the 10-year risk of
MDS or AML is about 3% for every year of melphalan
treatment.
Discussion
Considerable evidence has accumulated to suggest that
cytotoxic agents in general, and the biological alkylating
agents in particular, induce haemopoietic neoplasia in
patients suffering from myelomatosis. However, alkylating
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Figure 4 Predicted prevalence of MDS or AML for 0, 1, 2, 3, 5
years, indefinite, or alternating melphalan treatment based on an
absolute risk model using the last five years exposure. See text
for details.
agents are of value in the management of the disease and the
occurrence of haemopoietic neoplasia in a small minority of
patients is not in itself a reason for abandoning their use.
Appropriate analysis might show, for example, that the risk
of inducing haemopoietic neoplasia was related to some
aspect of the method of administration, and that by
changing the treatment regimen it could be considerably
reduced without altering the efficacy in controlling the
disease. Our findings indicate that melphalan, as
administered in the first two MRC myelomatosis trials (1964
to 1972) was more oncogenic than cyclophosphamide, and
they suggest that each year of treatment will lead to a 3%
prevalence of haemopoietic neoplasia in long term survivors.
It is important to keep in mind the limitations of the data
we have presented. Although patients were randomised
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between two different alkylating agents, considerable
uncontrolled crossing over between treatments did occur,
especially in long term survivors. This necessarily
complicated the analysis and we view our calculations of
dose-response curves as rough estimates, and our
observation on latency as a hypothesis in need of further
testing. It is also possible that time since diagnosis of
myeloma itself is a factor in the development of MDS or
AML, although the differences between melphalan and
cyclophosphamide treated patients suggest more is involved.
Detailed studies on large numbers of patients will be needed
to resolve these issues.
If melphalan were the only drug or the best drug capable
of controlling myelomatosis, it would be desirable to reduce
the period of administration to the shortest consistent with
optimal control. In the third MRC trial (MRC, 1980b) it
was indeed found that, for good risk patients, there was no
therapeutic advantage in continuing treatment beyond one
year. The lack of advantage in continued treatment has been
confirmed in the fourth MRC trial (MRC, 1985) in which
patients randomised to receive one further year of chemo-
therapy after having achieved a stable 'plateau' phase
(defined as no downward trend in paraprotein levels for six
months) have fared no better than those who stopped
cytotoxic treatment at plateau. In the first trial, the protocol
called for melphalan to be administered continuously at low
daily dosage, whilst in the second it was administered at
higher daily dosage for 7 consecutive days every month.
There was no significant difference in oncogenicity between
the two schedules, though the numbers are not large enough
to draw a firm conclusion on this.
Acute myeloid leukaemia was the first neoplasm to be
associated with the long-term administration of alkylating
agents and much effort has gone into the estimation of the
frequency of its occurrence. However, in the great majority
of cases of drug-induced leukaemia, the terminal overt acute
leukaemia develops from a bone marrow already abnormal
as a result of drug-induced neoplasia. This takes the form of
grossly disturbed and ineffective haemopoiesis involving all
three haemopoietic cell lineages, and is probably a clonal
proliferation of a pluripotential stem cell because clonal
chromosomal abnormalities are found in almost every case
(Nowell et al., 1978; Rowley, 1983; Pedersen-Bjergaard et al.,
1984). The ineffective haemopoiesis results in cytopenias
affecting one, two or all three cell lines and the resulting
clinical and haematological states are now known as the
myelodysplastic syndromes (MDS). Their rate of progression
is variable and the patients may survive for months or years.
A majority of the patients die as a result of the cytopenias,
but most of the remainder die from acute myeloid leukaemia
which develops as a result of the malignant transformation
of the already neoplastic myelodysplastic stem cell. Rarely,
the terminal leukaemia is of lymphoid origin suggesting that
the dysplastic stem cell is a pre-lymphoid pre-myeloid cell
(Pereira et al., 1985). MDS is occasionally found in the bone
marrow in myelomatosis before any treatment has been
administered (Mufti et al., 1983). Indeed, the increasing
incidence of leukeamia with the duration of myelomatosis
has been attributed to a special susceptibility of
myelomatosis patients to the development of acute leukaemia
(Bergsagel, 1982). If this were so, it would be difficult to
explain the clear relationship we have found with melphalan
treatment.
Attempts to estimate the oncogenic potential of cytotoxic
drugs therefore require the recording of cases of MDS as
well as those of overt acute myeloid leukaemia. It is true
that, in the past, at least some cases of MDS would have
been diagnosed as leukaemia (as in four of the cases
included in our report on the first trial) but the proportion is
unknown; it is likely, too, that some who died from MDS
without having progressed to overt acute myeloid leukaemia
would not have been recorded. Thus the true incidence of
drug-induced haemopoietic ncplasia may have been under-
estimated. In our own series we have followed the
recommendation of the FAB cooperative group which
proposed semiquantitative guidelines for distinguishing the
MDS from overt acute myeloid leukaemia. Of the 12 cases
only one was found to have overt leukaemia. In 9 of the
others only MDS could be documented (six with refractory
anaemia with excess of blasts (RAEB), and three of RAEB-
in-transformation), while in two cases slides were not
available to review the diagnosis. All twelve cases are
considered as a single group in the analysis.
Drug-induced haemopoietic neoplasia is an excellent
model for examining the biology of chemical carcinogenesis.
It may also throw light on the transformation of cells by
environmental carcinogens, because the primary myelo-
dysplastic syndromes of old age, whose essential features are
identical with those of the drug-induced MDS, are increasing
in frequency as the age structure of the population is
changing. Finally, the study of drug-induced haemopoietic
neoplasia may help in the identification of persons
particularly susceptible to specific chemical carcinogens of
both medical and environmental origin.
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